Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: The Lancet Oncology, 25, 7, S. 922-932
- Ereignis
-
Veröffentlichung
- (wo)
-
Augsburg
- (wer)
-
Universität Augsburg
- (wann)
-
2024
- Ereignis
-
Veröffentlichung
- (wer)
-
Elsevier BV
- (wann)
-
2024
- Urheber
-
Corbacioglu, Selim
Lode, Holger
Ellinger, Susanne
Zeman, Florian
Suttorp, Meinolf
Escherich, Gabriele
Bochennek, Konrad
Gruhn, Bernd
Lang, Peter
Rohde, Marius
Debatin, Klaus Michael
Steinbach, Daniel
Beilken, Andreas
Ladenstein, Ruth
Spachtholz, Rainer
Heiss, Peter
Hellwig, Dirk
Tröger, Anja
Koller, Michael
Menhart, Karin
Riemenschneider, Markus J.
Zoubaa, Saida
Kietz, Silke
Jakob, Marcus
Sommer, Gunhild
Heise, Tilman
Hundsdörfer, Patrick
Kühnle, Ingrid
Dilloo, Dagmar
Schönberger, Stefan
Schwabe, Georg
von Luettichau, Irene
Graf, Norbert
Schlegel, Paul-Gerhardt
Frühwald, Michael
Jorch, Norbert
Paulussen, Michael
Schneider, Dominik T.
Metzler, Markus
Leipold, Alfred
Nathrath, Michaela
Imschweiler, Thomas
Christiansen, Holger
Schmid, Irene
Crazzolara, Roman
Niktoreh, Naghmeh
Cario, Gunnar
Faber, Joerg
Demmert, Martin
Babor, Florian
Fröhlich, Birgit
Bielack, Stefan
Bernig, Toralf
Greil, Johann
Eggert, Angelika
Simon, Thorsten
Foell, Juergen
- DOI
-
10.1016/s1470-2045(24)00202-x
- URN
-
urn:nbn:de:bvb:384-opus4-1138672
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Corbacioglu, Selim
- Lode, Holger
- Ellinger, Susanne
- Zeman, Florian
- Suttorp, Meinolf
- Escherich, Gabriele
- Bochennek, Konrad
- Gruhn, Bernd
- Lang, Peter
- Rohde, Marius
- Debatin, Klaus Michael
- Steinbach, Daniel
- Beilken, Andreas
- Ladenstein, Ruth
- Spachtholz, Rainer
- Heiss, Peter
- Hellwig, Dirk
- Tröger, Anja
- Koller, Michael
- Menhart, Karin
- Riemenschneider, Markus J.
- Zoubaa, Saida
- Kietz, Silke
- Jakob, Marcus
- Sommer, Gunhild
- Heise, Tilman
- Hundsdörfer, Patrick
- Kühnle, Ingrid
- Dilloo, Dagmar
- Schönberger, Stefan
- Schwabe, Georg
- von Luettichau, Irene
- Graf, Norbert
- Schlegel, Paul-Gerhardt
- Frühwald, Michael
- Jorch, Norbert
- Paulussen, Michael
- Schneider, Dominik T.
- Metzler, Markus
- Leipold, Alfred
- Nathrath, Michaela
- Imschweiler, Thomas
- Christiansen, Holger
- Schmid, Irene
- Crazzolara, Roman
- Niktoreh, Naghmeh
- Cario, Gunnar
- Faber, Joerg
- Demmert, Martin
- Babor, Florian
- Fröhlich, Birgit
- Bielack, Stefan
- Bernig, Toralf
- Greil, Johann
- Eggert, Angelika
- Simon, Thorsten
- Foell, Juergen
- Universität Augsburg
- Elsevier BV
Entstanden
- 2024
Ähnliche Objekte (12)
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death
Glioma and temozolomide induced alterations in gut microbiome
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Mesostructured silica matrix for irinotecan delivery systems
Temozolomide-associated blepharoconjunctivitis: a case report
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death
Glioma and temozolomide induced alterations in gut microbiome
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Mesostructured silica matrix for irinotecan delivery systems
Temozolomide-associated blepharoconjunctivitis: a case report
Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity
Fasudil increases temozolomide sensitivity and suppresses temozolomide-resistant glioma growth via inhibiting ROCK2/ABCG2
Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death
Glioma and temozolomide induced alterations in gut microbiome
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
Temozolomide promotes genomic and phenotypic changes in glioblastoma cells
Irinotecan-Induced Transient Dysarthria: Case Series and Updated Literature Review
Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma
Mesostructured silica matrix for irinotecan delivery systems